AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 NOV 5 - (NewsRx.com & NewsRx.net) -- Heat shock protein derived from a non-autologous tumor can be used as an anti-tumor vaccine.
According to published research from Ireland, "Antigenic cross-reactivity between certain tumors has allowed the development of more widely applicable, major histocompatibility complex-disparate (allogeneic) whole-cell vaccines. This principle should also allow heat shock proteins (hsp) derived from certain tumors (and carrying cross-reactive antigens) to be used as vaccines to generate anti-tumor immunity in a range of cancer patients."
"Here, hsp70 derived from gp70-antigen+ B16 melanoma generated cytotoxic-T-lymphocyte-mediated immune protection in BALB/c mice against challenge with gp70-antigen+ CT26 colorectal tumor cells," reported David G. Casey at the National University of Ireland and colleagues throughout the U.K. "Using ovalbumin as a model tumor antigen, it is shown that hsp70 enhances peptide re-presentation by dendritic cells via class I over ...
Source: HighBeam Research, Heat shock protein from a non-autologous tumor used as anti-tumor...